Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Reasons for treatment discontinuation in multiple myeloma: Insights from the PREAMBLE registry

Ravi Vij, Mark Fiala, David Cella et al. Nov 03, 2025 pp. 6345-6345 10.1182/blood-2025-6345

Abstract Introduction : Despite treatment (tx) advances in multiple myeloma (MM), patients (pts) continue to face shortened survival compare...

CD7-targeted CAR-T cell therapy showed a high efficacy for 30 patients with relapsed or refractory central nervous system T-cell lymphoblastic leukemia/lymphoma

Junfang Yang, Xian Zhang, Jingjing Li et al. Nov 03, 2025 pp. 1039-1039 10.1182/blood-2025-1039

Abstract Introduction CD7-targeted chimeric antigen receptor (CAR) T-cell therapy has demonstrated efficacy and safety in treating T-cell ac...

Clinical spectrum of hereditary hemorrhagic telangiectasia (HHT): Data from the comprehensive hht outcomes registry of the United States (CHORUS)

Hanny Al-Samkari, Cassi Friday, Raj Kasthuri et al. Nov 03, 2025 pp. 309-309 10.1182/blood-2025-309

Abstract BACKGROUND Hereditary hemorrhagic telangiectasia (HHT) is the second most common inherited bleeding disorder (IBD) worldwide, affli...

Implementation of an innovative hospital at home program for patients with hematalogic malignancies

Nikesh Shah, Joanna Barris, Colleen Mcintosh et al. Nov 03, 2025 pp. 520-520 10.1182/blood-2025-520

Abstract Introduction: Patients with aggressive hematologic malignancies have high rates of inpatient admissions. Specifically, patients rec...

SRSF2 mutation-induced CHD8 exon skipping represents a novel pathogenic mediator and therapeutic dependence in chronic myelomonocytic leukemia (CMML)

Yu-Hung Wang, Kristian Gurashi, Laura Guest et al. Nov 03, 2025 pp. 676-676 10.1182/blood-2025-676

Abstract Introduction SRSF2, a splicing factor regulating both constitutive and alternative splicing (AS), is mutated in >40% of CMML...

Direct IL-6 sequestration with siltuximab rescues CAR T-cell proliferation from inflammatory suppression: A longitudinal multi-omic analysis supporting a paradigm shift in CRS management

Ruijie He, Xuelin Han, Chen Chen et al. Nov 03, 2025 pp. 2386-2386 10.1182/blood-2025-2386

Abstract Background: Interleukin-6 (IL-6) drives Cytokine Release Syndrome (CRS), a major toxicity of CAR T-cell therapy. The standard-of-ca...

The impact of public versus private health care services in the treatment of diffuse large B-cell lymphoma in Brazil: An analysis from the bra-DLBCL multicenter, retrospective real-world registry

Talita Silveira, Guilherme Perini, Larissa Teixeira et al. Nov 03, 2025 pp. 8011-8011 10.1182/blood-2025-8011

Abstract Introduction Despite the improvement in management of diffuse large B-cell lymphoma (DLBCL) in recent years, th...

Association of obstructive sleep apnea with readmission and healthcare utilization in adults with sickle cell disease: A propensity-matched analysis of national readmission data

Mariana Marrero Castillo, Benedict Amalraj, Shidestini Martinez et al. Nov 03, 2025 pp. 2663-2663 10.1182/blood-2025-2663

Abstract Background: Obstructive sleep apnea (OSA) is a prevalent and consequential comorbidity in sickle cell disease (SCD). The nocturnal...

Treatment with an EYA2 inhibitor prolongs survival of SIX1-expressing murine T-cell leukemias

Waitman Aumann, Huifeng Shen, Julie Bashirian et al. Nov 03, 2025 pp. 6821-6821 10.1182/blood-2025-6821

Abstract Background: The CALM-AF10 (PICALM-MLLT10) fusion, found in 5-10% of pediatric T-ALLs (T-cell acute lymphoblasti...

Assessing the prevalence of sickle cell retinopathy in clinical practice

Elexis Price, Arjun Bhatt, Siera Gollan et al. Nov 03, 2025 pp. 4750-4750 10.1182/blood-2025-4750

Abstract Sickle cell retinopathy (SCR) is a common, vision-threatening complication of sickle cell disease (SCD), yet adherence to national...

Trends and outcomes associated with atrial fibrillation in patients hospitalised with non-Hodgkin lymphoma - insights from national inpatient sample (NIS) database (2016-2022)

Faizan Ahmed, Haziq Ahmad, Abdullah Masood et al. Nov 03, 2025 pp. 8087-8087 10.1182/blood-2025-8087

Abstract Background: Non-Hodgkin Lymphoma (NHL) is one of the most widespread malignancies in the United States. It constitutes approximatel...

Identifying treatment response in AML through a multi-omics classifier of malignant cell states

Yang Song, Linjie Wu, Xiaohuan Qin et al. Nov 03, 2025 pp. 3487-3487 10.1182/blood-2025-3487

Abstract Background: Therapy resistance in Acute Myeloid Leukemia (AML) remains a major clinical challenge, yet its underlying cellular and m...

Inhibition of telomerase and ALT pathways in MDS/AML cell lines

Harouna Ousmane Sow, Macoura Gadji, Brett Houston et al. Nov 03, 2025 pp. 6808-6808 10.1182/blood-2025-6808

Abstract Background: The ability of human cancer cells to maintain telomere length over successive cell divisions rapidly emerged as an adap...

Epidemiological and molecular analysis of thalassemia (Beta Globin Gene) in the heterogeneous population of gwadar, Pakistan

Shali Anwar, Natasha Ali, Afsar Mian et al. Nov 03, 2025 pp. 4672-4672 10.1182/blood-2025-4672

Abstract Heterogeneous Population of Gwadar, Pakistan Introduction and objective: Beta-thalassemia remains one of the most serious hereditar...

Central nervous system involvement in acute myeloid leukemia: A national analysis of inpatient outcomes using the 2022 national inpatient sample

Inae Park, Mohit Mirchandani, Yoonhee Choi et al. Nov 03, 2025 pp. 3387-3387 10.1182/blood-2025-3387

Abstract Background: Central nervous system (CNS) involvement in acute myeloid leukemia (AML) is rare but portends worse outcomes. However, p...

Pirtobrutinib, a non-covalent BTK inhibitor, enhances T-cell anti-tumor immunity in chronic lymphocytic leukemia (CLL)

Sonia Rodriguez-Rodriguez, Tiana Huynh, Vi Lam et al. Nov 03, 2025 pp. 3878-3878 10.1182/blood-2025-3878

Abstract INTRODUCTION Covalent Bruton tyrosine kinase inhibitors (cBTKi) transformed the treatment of CLL and mantle cell lymphoma (MCL). cBT...

Evaluation of endothelial activation and stress index (EASIX) formulae in patients with compound heterozygosity for hb s and β-thalassemia: Correlation with specific proteins of disease activity

Eleni Gavriilaki, Maria Dimopoulou, Paschalis Evangelidis et al. Nov 03, 2025 pp. 6502-6502 10.1182/blood-2025-6502

Abstract Background: Activation of vascular endothelium, the inner lining of blood vessels, has been previously reported in sickle cell dise...

Subtype-specific son isoform expression in Acute Myeloid Leukemia revealed by targeted long-read RNA sequencing

Mostafa Mohamed, Amr Elkholy, Saeed ZakaKhosravi et al. Nov 03, 2025 pp. 7009-7009 10.1182/blood-2025-7009

Abstract Background: The SON gene encodes a large nuclear protein that plays essential roles in RNA splicing, nuclear speckle integrity, and...

Prospective analysis and clinical implications of therapy-related clonal hematopoiesis in adolescent and young adult survivors of acute lymphoblastic leukemia

Habib El-Khoury, Ella Postich, Diren Arda Karaoglu et al. Nov 03, 2025 pp. 3319-3319 10.1182/blood-2025-3319

Abstract Adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) are exposed to cytotoxic chemotherapy early in life, whi...

Venous thromboembolism in hospitalized tuberculosis patients: Incidence, racial disparities, and factors associated with in-hospital mortality: An observational study

Lakshmi Kattamuri, Kunal Sharma, Abhizith Deoker et al. Nov 03, 2025 pp. 3133-3133 10.1182/blood-2025-3133

Abstract Background: Tuberculosis (TB) induces a significant systemic hypercoagulable state driven by chronic inflammation, endothelial dysfu...

Protamine Overdose–Associated coagulopathy in the setting of post-PCI RCA dissection and cardiac tamponade: A hematologic management dilemma

Ilias Jerrar, Adnan Lokhandwala, Reem Akel et al. Nov 03, 2025 pp. 6673-6673 10.1182/blood-2025-6673

Abstract Background: Protamine sulfate is widely used to reverse heparin anticoagulation in interventional cardiology. W...

The TEMPI syndrome: Unique patient specific monoclonal antibodies as tools for target antigen discovery

David Sykes, Jens Wrammert, Wilfried Schroyens Nov 03, 2025 pp. 2142-2142 10.1182/blood-2025-2142

Abstract BACKGROUND. In 2011, we discovered the TEMPI syndrome. TEMPI is a rare monoclonal gammopathy of clinical significance (MGCS) with p...

Safety and immunomodulatory effects of siltuximab prophylaxis prior to standard of care CD19 directed chimeric antigen receptor T-cell (CD19.CART) therapy for B-cell lymphomas: Final phase I trial results

Nathan Denlinger, NoJoon Song, Negin Goodarzi et al. Nov 03, 2025 pp. 2385-2385 10.1182/blood-2025-2385

Abstract Introduction: CD19.CART is highly effective for B-cell non-Hodgkin lymphomas (NHL). However, cytokine release syndrome (CRS) and im...

S100A12-Orchestrated Macrophage-ER stress crosstalk in MDS: Mechanisms and precision therapeutic targeting

Li Zhang, Liansheng Zhang, Ting Niu et al. Nov 03, 2025 pp. 6769-6769 10.1182/blood-2025-6769

Abstract Background: Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders originating in the bone marrow. Current ch...

Rare germline complement gene variants in severe aplastic anemia

Luca Arcuri, Emma Groarke, Ruba Shalhoub et al. Nov 03, 2025 pp. 1421-1421 10.1182/blood-2025-1421

Abstract Background: Severe aplastic anemia (SAA) and paroxysmal nocturnal hemoglobinuria (PNH) are strongly associated; the AA/PNH syndrome...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page